Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier

Ann Rheum Dis. 2022 Dec;81(12):e251. doi: 10.1136/annrheumdis-2020-218960. Epub 2020 Oct 6.
No abstract available

Keywords: pulmonary fibrosis; scleroderma; systemic; therapeutics.

Publication types

  • Comment

MeSH terms

  • Humans
  • Indoles / adverse effects
  • Lung Diseases, Interstitial* / complications
  • Lung Diseases, Interstitial* / etiology
  • Protein Kinase Inhibitors
  • Scleroderma, Systemic* / complications
  • Scleroderma, Systemic* / drug therapy

Substances

  • nintedanib
  • Indoles
  • Protein Kinase Inhibitors